



(51) International Patent Classification:

A61K 9/10 (2006.01) A61P 25/18 (2006.01)
A61K 31/495 (2006.01)

(21) International Application Number:

PCT/CN2023/081984

(22) International Filing Date:

16 March 2023 (16.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/320,696 17 March 2022 (17.03.2022) US

(71) Applicant: **ANXO PHARMACEUTICAL CO., LTD.**
[CN/CN]; 8F-3, No. 206, Sec. 2, Nanking E. Rd., Taipei
City, Taiwan 10489 (CN).

(72) Inventors: **LIU, I-Hsiang**; 8F-3, No. 206, Sec. 2, Nanking
E. Rd., Taipei City, Taiwan 10489 (CN). **CHANG, Kuei-
Hua**; 8F-3, No. 206, Sec. 2, Nanking E. Rd., Taipei City,
Taiwan 10489 (CN). **JHAN, Hua-Jing**; 8F-3, No. 206,
Sec. 2, Nanking E. Rd., Taipei City, Taiwan 10489 (CN).
CHEN, Tse-Hsien; 8F-3, No. 206, Sec. 2, Nanking E. Rd.,
Taipei City, Taiwan 10489 (CN). **SU, Chia-Yu**; 8F-3, No.
206, Sec. 2, Nanking E. Rd., Taipei City, Taiwan 10489

(CN), **JIAN, Chi-Heng**; 8F-3, No. 206, Sec. 2, Nanking E.
Rd., Taipei City, Taiwan 10489 (CN). **HSU, Chun-Wei**;
8F-3, No. 206, Sec. 2, Nanking E. Rd., Taipei City, Taiwan
10489 (CN).

(74) Agent: **TIE CHI PATENT FIRM**; Rm. 705, 7F, Jia-
long International Tower, No. 19 Chaoyang Park Road,
Chaoyang District, Beijing 100026 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: INJECTABLE DEPOT FORMULATION COMPRISING CARIPRAZINE FREE BASE PARTICLES




FIG. 1

(57) Abstract: Disclosed herein is an injectable depot formulation and use thereof for treating a mental disorder. The injectable depot formulation comprises cariprazine free base particles and a pharmaceutically acceptable carrier. The cariprazine free base particles have a median particle size by volume (Dv50) ranging from 0.5 μm to 100 μm .

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))